# InspireMD, Inc.: overview NSPR · Nasdaq · CIK 1433607 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/nspr.md) · [Financials](/companies/nspr/financials.md) · [Filings](/companies/nspr/filings.md) · [Insiders](/companies/nspr/insiders.md) Latest reported revenue: [$1.8m](/filings/0001493152-26-038438.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 14, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001493152-26-038438). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [1.8](/filings/0001493152-25-021503.md) | [1.9 d](/filings/0001493152-26-010886.md) | [1.5](/filings/0001493152-26-021636.md) | [1.8](/filings/0001493152-26-038438.md) | [2.5](/filings/0001493152-25-021503.md) | [3.1 d](/filings/0001493152-26-010886.md) | [3.4](/filings/0001493152-26-021636.md) | [1.8](/filings/0001493152-26-038438.md) | | Gross margin | % | [22.9%](/filings/0001493152-25-021503.md) | [24.1% d](/filings/0001493152-26-010886.md) | [19.1%](/filings/0001493152-26-021636.md) | [17.6%](/filings/0001493152-26-038438.md) | [34.2%](/filings/0001493152-25-021503.md) | [37.5% d](/filings/0001493152-26-010886.md) | [20.2%](/filings/0001493152-26-021636.md) | [(43.7%)](/filings/0001493152-26-038438.md) | | Operating margin | % | [(467.5%)](/filings/0001493152-25-021503.md) | [(480.6%) d](/filings/0001493152-26-010886.md) | [(749.5%)](/filings/0001493152-26-021636.md) | [(732.2%)](/filings/0001493152-26-038438.md) | [(517.3%)](/filings/0001493152-25-021503.md) | [(383.7%) d](/filings/0001493152-26-010886.md) | [(411.4%)](/filings/0001493152-26-021636.md) | [(815.6%)](/filings/0001493152-26-038438.md) | | Net margin | % | [(435.9%)](/filings/0001493152-25-021503.md) | [(470.7%) d](/filings/0001493152-26-010886.md) | [(730.3%)](/filings/0001493152-26-021636.md) | [(739.7%)](/filings/0001493152-26-038438.md) | [(503.7%)](/filings/0001493152-25-021503.md) | [(373.5%) d](/filings/0001493152-26-010886.md) | [(402.9%)](/filings/0001493152-26-021636.md) | [(808.8%)](/filings/0001493152-26-038438.md) | | Diluted EPS | $ per share | [(0.16)](/filings/0001493152-25-021503.md) | not reported | [0.22](/filings/0001493152-26-021636.md) | [(0.26)](/filings/0001493152-26-038438.md) | [(0.17)](/filings/0001493152-25-021503.md) | not reported | [(0.16)](/filings/0001493152-26-021636.md) | [(0.17)](/filings/0001493152-26-038438.md) | | Free cash flow | $m | [(6.1) d](/filings/0001493152-25-021503.md) | [(7.1) d](/filings/0001493152-26-010886.md) | [(9.2)](/filings/0001493152-26-021636.md) | [(8.9) d](/filings/0001493152-26-038438.md) | [(9.0) d](/filings/0001493152-25-021503.md) | [(9.7) d](/filings/0001493152-26-010886.md) | [(12.5)](/filings/0001493152-26-021636.md) | [(11.2) d](/filings/0001493152-26-038438.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [4.5](/filings/0001493152-23-009598.md) | [5.2](/filings/0001493152-24-008850.md) | [6.2](/filings/0001493152-25-009909.md) | [7.0](/filings/0001493152-26-010886.md) | [9.0](/filings/0001493152-26-010886.md) | | Gross margin | % | [16.8%](/filings/0001493152-23-009598.md) | [21.6%](/filings/0001493152-24-008850.md) | [29.1%](/filings/0001493152-25-009909.md) | [21.5%](/filings/0001493152-26-010886.md) | [29.5%](/filings/0001493152-26-010886.md) | | Operating margin | % | [(327.4%)](/filings/0001493152-23-009598.md) | [(361.9%)](/filings/0001493152-24-008850.md) | [(340.7%)](/filings/0001493152-25-009909.md) | [(478.0%)](/filings/0001493152-26-010886.md) | [(552.6%)](/filings/0001493152-26-010886.md) | | Net margin | % | [(331.9%)](/filings/0001493152-23-009598.md) | [(357.6%)](/filings/0001493152-24-008850.md) | [(321.0%)](/filings/0001493152-25-009909.md) | [(456.6%)](/filings/0001493152-26-010886.md) | [(543.3%)](/filings/0001493152-26-010886.md) | | Diluted EPS | $ per share | [(2.03)](/filings/0001493152-22-006180.md) | [(2.35)](/filings/0001493152-24-008850.md) | [(0.82)](/filings/0001493152-25-009909.md) | [(0.76)](/filings/0001493152-26-010886.md) | [(0.76)](/filings/0001493152-26-010886.md) | | Free cash flow | $m | [(13.6)](/filings/0001493152-23-009598.md) | [(16.0)](/filings/0001493152-24-008850.md) | [(16.8)](/filings/0001493152-25-009909.md) | [(23.3)](/filings/0001493152-26-010886.md) | [(36.8)](/filings/0001493152-26-010886.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareBasicAndDiluted; Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/nspr/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [Rosalind Advisors, Inc.](/funds/1622627.md) | 2026-06-30 | $2.7m | 3,905,743 | | Unchanged | | [Aberdeen Group plc](/funds/1716774.md) | 2026-06-30 | $2.6m | 3,698,364 | | Added +525,000 | | [Nantahala Capital Management, LLC](/funds/1472322.md) | 2026-06-30 | $2.4m | 3,376,484 | | Unchanged | | [Nantahala Capital Management, LLC](/funds/1472322.md) | 2026-06-30 | $2.4m | 3,376,484 | | Unchanged | | [ORBIMED ADVISORS LLC](/funds/1055951.md) | 2026-06-30 | $2.2m | 3,133,405 | | Unchanged | | [Parkman Healthcare Partners LLC](/funds/1777015.md) | 2026-06-30 | $1.7m | 2,416,518 | | Unchanged | | [MARSHALL WACE, LLP](/funds/1318757.md) | 2026-06-30 | $1.3m | 1,860,405 | | Unchanged | | [Soleus Capital Management, L.P.](/funds/1802630.md) | 2026-06-30 | $732.1k | 1,045,708 | | Unchanged | | [PURA VIDA INVESTMENTS, LLC](/funds/1590144.md) | 2026-06-30 | $315.4k | 450,517 | | Unchanged | | [Affiance Financial, LLC](/funds/1723681.md) | 2026-06-30 | $175.3k | 250,370 | | Unchanged | ## Recent filings [All 1,161 filings](/companies/nspr/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-09-21 | 09:12 ET | [8-K](/filings/0001493152-26-043488.md) | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001493152-26-043488 | | 2026-08-17 | 07:05 ET | [8-K](/filings/0001493152-26-038624.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001493152-26-038624 | | 2026-08-14 | 16:30 ET | [10-Q](/filings/0001493152-26-038438.md) | Quarterly report, period 2026-06-30 | 0001493152-26-038438 | | 2026-07-29 | 17:00 ET | [8-K](/filings/0001493152-26-035220.md) | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001493152-26-035220 | | 2026-07-23 | 17:00 ET | [8-K](/filings/0001493152-26-034430.md) | 3.01 Delisting notice; 9.01 Financial statements and exhibits | 0001493152-26-034430 | | 2026-07-02 | 17:00 ET | [8-K](/filings/0001493152-26-031945.md) | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001493152-26-031945 | | 2026-06-11 | 08:05 ET | [8-K](/filings/0001493152-26-028221.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001493152-26-028221 | | 2026-06-03 | 16:05 ET | [8-K](/filings/0001493152-26-027045.md) | 5.03 Amendment to articles or bylaws; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001493152-26-027045 | | 2026-05-22 | 16:05 ET | [8-K](/filings/0001493152-26-025017.md) | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001493152-26-025017 | | 2026-05-07 | 08:53 ET | [10-Q](/filings/0001493152-26-021636.md) | Quarterly report, period 2026-03-31 | 0001493152-26-021636 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001493152-26-010886.md), filed Mar 18, 2026. ## Forecast league Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/4a6dd273-e1ae-4d10-a3fd-61ae3365dfca) ## About the filer - CIK: 1433607 - Tickers: NSPR - Exchange: Nasdaq - SIC code: 3841 Surgical & Medical Instruments & Apparatus - State of incorporation: DE - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:39 ET. No prices; not investment advice.